Philadelphia, PA (November 6, 2018) – Oncoceutics, Inc. announced that it will host an investigator meeting and that initial efficacy data of its lead compound ONC201 in patients with H3 K27M-mutant gliomas will be presented at the 2018 Annual Meeting of the Society for Neuro-Oncology in New Orleans, on November 15th to November 18th. The
Philadelphia, PA (September 10, 2018) – Oncoceutics, Inc. announced the receipt of a Small Business Innovation Research (SBIR) Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR Bridge Award will allow Oncoceutics to expand and accelerate its clinical trials evaluating ONC201 in patients with a specific type of lethal brain cancer
Philadelphia, PA (July 31, 2018) – Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology. Oncoceutics developed this portfolio of chemical compounds that target G protein-coupled receptors (GPCRs) using the unique core chemical structure of the
Philadelphia, PA (May 29, 2018) – Oncoceutics, Inc. announced that two abstracts will be presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) that will highlight clinical success of the company’s lead compound in treating high-grade gliomas (HGG), including those that harbor the H3 K27M mutation. The first abstract, entitled
Business Development